Endo Withdraws Opana Painkiller From Market at FDA’s Request Post author:Sam Post published:July 6, 2017 Post category:Drug Industry Daily Endo will withdraw Opana ER from the market, following an FDA request in June. Source: Drug Industry Daily You Might Also Like Drugmakers Call Mifepristone Ruling a ‘Legal Overstep’ of FDA Authority April 10, 2023 CMS: Part D Plans Will Allow Indication-Based Formularies in 2020 August 30, 2018 Brazilian Manufacturer Called Out for Slew of Violations September 21, 2018